FibroGen Inc (NASDAQ:FGEN) was the target of some unusual options trading on Friday. Investors purchased 2,431 call options on the company. This represents an increase of 2,631% compared to the average volume of 89 call options.

A number of equities research analysts recently issued reports on the company. BidaskClub cut FibroGen from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. ValuEngine cut FibroGen from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Mizuho reiterated a “hold” rating and set a $61.00 price target on shares of FibroGen in a research report on Thursday, November 9th. Stifel Nicolaus reiterated a “buy” rating and set a $80.00 price target on shares of FibroGen in a research report on Thursday, September 14th. Finally, Jefferies Group reiterated a “buy” rating and set a $75.00 price target on shares of FibroGen in a research report on Tuesday, September 12th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $65.67.

Shares of FibroGen (NASDAQ:FGEN) opened at $42.40 on Monday. FibroGen has a 52-week low of $19.25 and a 52-week high of $60.15. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.83 and a current ratio of 10.83.

In related news, insider K Peony Yu sold 2,851 shares of the business’s stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $43.70, for a total value of $124,588.70. Following the sale, the insider now directly owns 162,086 shares in the company, valued at approximately $7,083,158.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kalevi Kurkijarvi sold 2,000 shares of the business’s stock in a transaction dated Tuesday, October 17th. The shares were sold at an average price of $52.24, for a total value of $104,480.00. Following the completion of the sale, the director now owns 26,000 shares in the company, valued at $1,358,240. The disclosure for this sale can be found here. Insiders sold a total of 344,346 shares of company stock worth $18,110,030 over the last 90 days. 13.60% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in FGEN. Russell Investments Group Ltd. increased its position in shares of FibroGen by 71.0% during the second quarter. Russell Investments Group Ltd. now owns 57,502 shares of the biopharmaceutical company’s stock valued at $1,857,000 after buying an additional 23,875 shares during the period. Great West Life Assurance Co. Can increased its position in shares of FibroGen by 107.0% during the second quarter. Great West Life Assurance Co. Can now owns 8,694 shares of the biopharmaceutical company’s stock valued at $280,000 after buying an additional 4,494 shares during the period. Schwab Charles Investment Management Inc. increased its position in shares of FibroGen by 15.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 272,574 shares of the biopharmaceutical company’s stock valued at $8,805,000 after buying an additional 36,201 shares during the period. First Trust Advisors LP bought a new stake in shares of FibroGen during the second quarter valued at about $599,000. Finally, Rhumbline Advisers increased its position in shares of FibroGen by 11.4% during the second quarter. Rhumbline Advisers now owns 68,167 shares of the biopharmaceutical company’s stock valued at $2,202,000 after buying an additional 6,986 shares during the period. Hedge funds and other institutional investors own 57.43% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.watchlistnews.com/fibrogen-sees-unusually-large-options-volume-fgen/1770494.html.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.